anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide the titled composition free from the problems of stability, irritation, etc., and having high absorbability through the rectum, by compounding a beta-lactam compound useful as an antibacterial agent with a specific amino acid-type anionic surface active agent as an absorption promoter. CONSTITUTION:The objective rectal application composition of beta-lactam compound is prepared by compounding a compound having beta-lactam ring (e.g. cephalosporin, cephamycin antibiotics, etc.) with an amino acid-type anionic surface active agent of formula (RCO- is fatty acid residue). The compound of formula is a known compound, and available, e.g. in the name of Amisoft CS-11 (product of Ajinomoto Ltd.). The compound of formula acts as an absorption promoter, and its amount is preferably 2-20W/W%. The problems of conventional rectal drug, e.g. poor stability, irritation, damage to the tissue, etc. are solved in the present composition, which has extremely high absorbability through the rectum.
Frontal fibrosing alopecia (FFA) is a scarring alopecia with fronto-temporo-parietal hairline recession. Although no proven treatment for FFA exists, dutasteride has been suggested as a potential treatment option. We aimed to evaluate the therapeutic response of oral dutasteride in FFA patients. The identification and selection of studies were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis 2020 criteria. To assess the risk of bias for each study, we used the Cochrane's risk of bias in non-randomized studies of interventions (ROBINS-I) assessment tool. A random effects model meta-analysis was performed. Estimated proportion of stabilization for eligible studies was calculated to evaluate the effectiveness of dutasteride for treating FFA. Among patients who achieved stabilization, subgroup analysis was conducted on those showing improvement. Seven studies including 366 patients who received oral dutasteride were identified. The estimated proportion of patients who experienced stabilization of FFA with oral dutasteride was 0.628 (95% CI: 0.398-0.859). In subgroup analyses of patients who experienced improvement, the estimated proportion of improvement was 0.356 (95% CI: 0.163-0.549). In this systematic review and meta-analysis, oral dutasteride revealed to be a good treatment option for disease stabilization or improvement in patients with FFA.
The invention discloses a Chinese medicinal compound extract for whitening and removing freckles and a preparation method thereof, relates to a medicament for whitening and removing the freckles, and solves the problems of slow curative effect, low cure rate and inconvenient administration of Chinese medicaments for a long term in the treatment for chloasma at present. The Chinese medicinal compound extract for whitening and removing the freckles is prepared from bupleurum, Chinese angelica, white paeony root, dogwood, large-head atractylodes rhizome, Indian buead, szechuan lovage rhizome, peach seed, white muscardine silkworm, roasted ginger, mint and radix glycyrrhizae preparata; and the product is prepared by adopting carbon dioxide supercritical extraction technology. The method has the advantages of simpleness and convenient operation, and can highly enrich active ingredients. Therefore, the bioavailability is improved; the pharmacological activity is obviously enhanced; and the obtained product has small volume and does not contain solid impurities which cannot be emulsified. The Chinese medicinal compound extract effectively suppresses the activity of tyrosinase and melanogensis, removes or improves the chloasma, and responds within about one month, and the cure rate reaches 99.98 percent. The Chinese medicinal compound extract can be used as an active ingredient for directly preparing an external medicinal preparation and cosmetics for whitening and removing the freckles, is easy to carry, and is convenient to use.
The aim of prehabilitation programs is to eliminate intraoperative complications by increasing the functional capacity and metabolic reserves of patients before surgical treatment and to accelerate recovery in the postoperative period. In addition, it helps the patient to maximize the existing capacity of the patient before the surgery, to know what will happen at each stage of the treatment to be applied to the patient, to feel better physically and spiritually and to understand the roles and responsibilities of the individual care of the patient, as well as making a significant contribution to the positive results of the operation. It is to provide exercise, psychological support, nutritional counseling and optimization of the underlying conditions by stopping negative health behaviors. There are non-eliminable criteria such as age, gender, comorbid diseases before surgery, as well as modifiable factors such as the regulation of the patients nutrition, ensuring psychological well-being, quitting smoking. In particular, some factors directly affect the state of well-being during the perioperative period. Thus, surgeries become safer.As a practice, the prehabilitation program (according to the surgery program) is planned in the preoperative period between 2-4 weeks Dec. Participants who do not comply with the program will be excluded from the sample
BACKGROUND/AIM: Perioperative inflammation and the nutritional status affect both short- and long-term oncological outcomes in various malignancies. We clarified the clinical impacts of the CRP-albumin-lymphocyte (CALLY) index in patients with esophageal cancer who received curative treatment.
PATIENTS AND METHODS: The present study included 180 patients who underwent curative treatment for esophageal cancer between 2005 and 2020. The prognosis and clinicopathological parameters were compared between a high-fibrinogen group and a low-fibrinogen group.
RESULTS: The 3- and 5-year overall survival rates were 50.0% and 42.6%, respectively, in the CALLY index-low group, and 75.9% and 66.6% in the CALLY index-high group. The differences between the two groups were statistically significant (p<0.001). Univariate and multivariate analyses demonstrated that the CALLY index was an independent prognostic factor [hazard ratio=2.310, 95% confidence interval=1.416-3.767, p<0.001]. Similar results were observed in recurrence-free survival. When comparing the details of postoperative surgical complications, there was a significant difference in the incidence of anastomotic leakage. The incidence of anastomotic leakage was 40.2% in the CALLY index-low group, while it was 27.5% in the CALLY index-high group (p=0.030).
CONCLUSION: The pretreatment CALLY index is one of the independent prognostic factors for esophageal cancer. The CALLY index might become a promising biomarker for the treatment and management of esophageal cancer.
Liposomal bupivacaine has gained interest in recent literature for its potential to be an effective adjunct to other pain control modalities in a multi-modal approach to post-operative pain control. Liposomal bupivacaine is an analgesic that is suspended in lipids to allow for gradual release of the analgesic over a 72-hour period (NAMDARI). From prior literature, the utilization of local analgesics infiltrated into surgical sites have been shown to reduce pain in the immediate post-operative period in foot and ankle surgery (GADEK). However, the evaluation of liposomal bupivacaine in foot and ankle surgery is limited. One prospective study found that the addition to liposomal bupivacaine to a multi-modal pain management protocol for forefoot surgery resulted in decreased pain scores during the first four post-operative days as well as fewer refills of opioid pain medication prescriptions, although both findings were not statically significant (ROBBINS). As the general medical community and public policy makers continue to focus on decreasing the amount of opioid pain medications prescribed and available in the community due to the opioid epidemic, liposomal bupivacaine has the potential to be a useful adjunct in the management of post-operative pain without reliance on opioid prescriptions. The goal of this investigation is to compare the efficacy of local administration of liposomal bupivacaine versus the efficacy of a peripheral nerve block in terms of post-operative pain scores after elective ankle and hindfoot surgery. The investigators hypothesize that there will not be a significant difference in the pain scores of these two groups in opioid naïve patients. Furthermore, this study aims to determine if there are differences in the amount of opioid medications utilized for post-operative pain control, patient satisfaction scores, functional outcomes, complications, and unscheduled healthcare contact between the two groups. In order to accomplish these aims, a randomized, controlled investigation will be conducted.
PROBLEM TO BE SOLVED: To obtain a composition which is lowly irritant to skin and hair, is highly foaming to give creamy foam within the range from weakly acidic to alkaline, and exhibits excellent detergency and good feeling of use by formulating a specific sugar ether carboxylic acid compound and an amphoteric surfactant. SOLUTION: A sugar ether carboxylic acid compound of the formula is employed. In the formula, R is 6-30C (on the average) alkyl, alkenyl or hydroxyalkyl; A is 2-3C alkylene; S is a residue of a 4-8C sugar alcohol; m is 0-10; n is 1-6; and M is H or a salt-forming cation. The wt. ratio of the sugar ether carboxylic acid compound (A) to an amphoteric surfactant (B) to be mixed is usually 10/90 to 95/5. The total amount of the components A and B compounded in the detergent composition is preferably 0.5-50 wt.% when the detergent is in a liquid form, 1-70 wt.% when in a pasty form and 1-80 wt.% when in a solid form.
BACKGROUND: Hepatoblastoma is the most frequent pediatric liver cancer. The current treatments lead to 80% of survival rate at 5 years. In this study, we evaluated the clinical relevance of molecular features to identify patients at risk of chemoresistance, relapse and death of disease.
METHODS: All the clinical data of 86 children with hepatoblastoma were retrospectively collected. Pathological slides were reviewed, tumor DNA sequencing (by whole exome, whole genome or target) and transcriptomic profiling with RNAseq or 300-genes panel were performed. Associations between the clinical, pathological, mutational and transcriptomic data were investigated.
RESULTS: High-risk patients represented 44% of our series and the median age at diagnosis was 21.9 months (range: 0-208). Alterations of the WNT/ß-catenin pathway and of the 11p15.5 imprinted locus were identified in 98% and 74% of the tumors, respectively. Other cancer driver genes mutations were only found in less than 11% of tumors. After neoadjuvant chemotherapy, disease-specific survival and poor response to neoadjuvant chemotherapy were associated with 'Liver Progenitor' (p = 0.00049, p < 0.0001) and 'Immune Cold' (p = 0.0011, p < 0.0001) transcriptomic tumor subtypes, SBS35 cisplatin mutational signature (p = 0.018, p = 0.001), mutations in rare cancer driver genes (p = 0.0039, p = 0.0017) and embryonal predominant histological type (p = 0.0013, p = 0.0077), respectively. Integration of the clinical and molecular features revealed a cluster of molecular markers associated with resistance to chemotherapy and survival, enlightening transcriptomic 'Immune Cold' and Liver Progenitor' as a predictor of survival independent of the clinical features.
CONCLUSIONS: Response to neoadjuvant chemotherapy and survival in children treated for hepatoblastoma are associated with genomic and pathological features independently of the clinical features.
NNZ-2566 reconstituted in bicarbonate buffer and normal saline. 6/8 subjects in each cohort (5 cohort in total) to receive NNZ-2566 experimental treatment.
<P>PROBLEM TO BE SOLVED: To provide a method for producing a colorless distillate and extract having antibacterial property and water-retention and excellent transparency and safety and containing a vegetable component and provide a cosmetic compounded with the distillate, etc.  <P>SOLUTION: The distillate is produced by pressing raw leaves and stalks of Sasa kurilensis nom. nov., and distilling the obtained juice at ≤70°C. The color number of the distillate is color number standard liquid 1 or under determined by Gardner color number test method. The pH of the distillate obtained without additional washing with water is 3.5-4.8 and the Sasa kurilensis water has a half value width of ≤60 Hz by the determination of radioactive isotope<SP>17</SP>O by NMR (nuclear magnetic resonance). The Sasa kurilensis extract is produced by mixing and dissolving the distillate with the residual liquid left after distillation and filtering the mixture. The transparent cosmetic having antibacterial property and water retention, almost free from color and odor and having excellent safety is produced by compounding the distillate or extract.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
TransAeris stimulation therapy adjunctive to continued mechanical ventilation will begin 24 hours after leaving the operating room, if subject remains on mechanical ventilation. TransAeris stimulator settings (stimulus intensity, stimulus frequency, and burst on/off) will be programmed to optimize diaphragm recruitment without compromising patient comfort.
Subjects randomized to hydroxychloroquine (HCQ). Subjects will receive 200-400 mg of HCQ (1-2 pills), based upon ideal body weight (IBW), taken daily for 12 months.
Up to 45 apparently healthy participants will be recruited at multiple sites. Eligible participants will complete a fitness test to measure pre-training maximal aerobic capacity (V̇O2max). Participants will start cycling on a stationary bike at a low intensity (30 W). The intensity will increase by 1 W every 3 seconds until volitional exhaustion or an inability to maintain a pedalling frequency of \>60 rpm. Expired O2 and CO2 will be continuously measured breath-by-breath using an online gas analyser. V̇O2max will be determined as the highest value for a 15-breath rolling average of V̇O2. V̇O2max will be accepted if at least 2 of the following criteria are met: volitional exhaustion / inability to maintain a pedal frequency of 60 rpm, RER\>1.10, a plateau in V̇O2, and/or heart rate within 10 bpm of the age predicted maximum (220-age).

Participants will then be randomised into one of 3 groups, performing either 1 or 2 REHIT training sessions per week, or no training intervention (control group). Randomisation will be performed using the sealed envelope method. Participants in the control group will be asked to maintain their regular lifestyle for 6 weeks. Participants in the training groups will perform 6 weeks of REHIT. Each REHIT session involves 10 min of unloaded pedalling interspersed with 2 all-out cycle sprints against a resistance equivalent to 7.5% of the participant's body weight. Sprint duration will be 10 s in week 1, 15 s in week 2, and 20 s in the remaining 4 weeks. The first sprint will finish at 2 min and the second sprint will finish at 6 min. Participants will be instructed to start pedalling as fast as they can \~2-3 s before applying the sprint resistance, and to keep pedalling as fast as they can during the sprint. Verbal encouragement will be provided. Heart rate and power output will be measured throughout each 10-minute exercise session. The post-training V̇O2max test will be scheduled 3 days following the last training session.
PURPOSE:To obtain the subject new compound, having actions as a potassium channel opener and useful as a vasodilator capable of manifesting strong vasodilator actions. CONSTITUTION:This compound is expressed by formula I [A and B are each N or CH; R1 and R2 are each H, a lower alkyl, a lower haloalkyl, a lower alkoxy, etc.; R3 is H, a (substituted) lower alkyl or a (substituted) aryl; R4 is a heterocyclic ring group, a carbamide, a carbothioamide, a cyanamide, etc.] and its pharmaceutically permissible salt, e.g. 2-ethyl-4-(1,2-dihydro-2- oxopyridyl)-6-nitroquinazoline. The compound of formula I is obtained by reacting a compound of formula II with a phosphorus halide, a phosphoryl halide or a thionyl halide, providing a compound of formula III (X is a halogen) and then reacting the resultant compound with a compound of the formula, R4H in the presence of a suitable base in an inert solvent at 0-150 deg.C.
Although cisplatin (CDDP) is an antineoplastic drug widely used for the treatment of various tumors, its toxicity on the reproductive system is a concern for patients. Ethyl pyruvate (EP) possesses potent antioxidant and anti-inflammatory activities. The objective of this study was to evaluate the therapeutic potential of EP on CDDP-mediated ovotoxicity for the first time. Rats were exposed to CDDP (5 mg/kg) and then treated with two doses of EP (20 and 40 mg/kg) for 3 days. Serum fertility hormone markers were evaluated using ELISA kits. Oxidative stress (OS), inflammation, endoplasmic reticulum stress (ERS) and apoptosis markers were also determined. In addition, how CDDP affects the nuclear factor erythroid 2-associated factor 2 (Nrf2) pathway and the effect of EP on this situation were also addressed. EP improved CDDP-induced histopathological findings and restored decreasing levels of fertility hormones. EP treatment also reduced the levels of CDDP-mediated OS, inflammation, ERS and apoptosis. In addition, EP attenuated CDDP-induced suppression in the levels of Nrf2 and its target genes, including heme oxygenase-1, NAD(P)H quinone dehydrogenase-1, superoxide dismutase and glutathione peroxidase. Histological and biochemical results showed that EP can have therapeutic effects against CDDP-induced ovotoxicity with antioxidant, anti-inflammatory and Nrf2 activator activities.
The present invention relates to a method for immobilizing target materials, preferably probiotics, proteins, and drugs, in a nanocellulose carrier by using bioprinting technology, and to a method for selectively releasing a target material in vivo using the carrier manufactured by the method. According to the present invention, a nanocellulose as a carrier can be used for food by having excellent biocompatibility as an organic synthetic fiber, and can be easily transferred by having excellent acid resistance, bile resistance, and mechanical properties. As a strategy for making a three-dimensional structure elaborately, it is easy to control sustained-release release because the target material (for example, probiotics, proteins, drugs, and the like) is immobilized (supported or encapsulated, bonded, and the like) to the nanocellulose carrier by using the 3D bioprinting technique. Thus, it is possible to easily control sustained release. In addition, it is possible to protect a target material from gastric acid and bile acid according to the selection of a cross-linked material. Also, it is possible to rapidly and selectively release a target material by an enzyme in the intestinal organs (the small intestine or the large intestine). A delivery system may be usefully applied to transfer health functional food firstly, and proteins, drugs, microorganisms, and the like secondly.
FIELD: medicine, pulmonology, pediatrics. SUBSTANCE: method involves carrying out of selective sanative bronchoscopy and administration of pulmonary surfactant as the preparation "surfactant-BL" which is administrated by a single dose or 2-3 times at break for 2-3 days in the amount 100-300 mg per one dose. Method provides high incidence of complete (or partial) recovery of atelectasis and decrease of patients treatment, decreases numbers of necessary sanative fibrobronchoscopies and probability of disease conversion to the chronic form. Invention can be used for treatment of children with acute bronchopneumonia complicated with atelectasis as bronchopneumonia complication. EFFECT: enhanced effectiveness of treatment. 2 cl, 1 tbl, 5 ex
Local inflammatory microenvironment in the early stage of myocardial infarction (MI) severely impaired cardiac recovery post-MI. Macrophages play a pivotal role in this process. A classical glycolytic inhibitor, 2-Deoxy-Glucose (2-DG), has been found to regulate the excessive pro-inflammatory macrophage polarization in the infarcted myocardium. This study investigated the effect of 2-DG-loaded chitosan/gelatin composite patch on the infarct microenvironment post-MI and its impact on cardiac repair. The results showed that the 2-DG patch significantly inhibited the expression of inflammatory cytokines, alleviated reactive oxygen species (ROS) accumulation, repressed the proinflammatory polarization of macrophages, attenuated local inflammatory microenvironment in the ischemic hearts, as well as improved cardiac function, reduced scar size, and promoted angiogenesis post-MI. In terms of mechanism, 2-DG exerts anti-inflammatory effects through inhibiting the NF-κB signaling pathway and reducing the assembly and activation of the NLRP3 inflammasome. These findings suggest that 2-DG composite patch may represent a promising therapeutic strategy for cardiac repair after MI.
Each dyad receives institution-specific usual care for 6 months as described in arm I. Accompanying parents also receive a book from the Blood and Marrow Transplant Information Network (BMT Infonet).
Patients in this group receive disulfiram for 8 weeks. The dosing schedule is fixed-flexible, starting at 250 mg every other day at week 1, 250 mg daily for week 2, 250 mg alternating with 500 mg for week 3, and 500 mg daily for week 4 to week 8. Dose increases are based on clinical judgment guided by patient tolerance, response, body weight, and side effects.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to compounds forming in vivo a biologically active drug reservoir composition which contains low-viscous nonliquid crystal mixtures of diacylglycerine, tocopherol, phosphatidylcholine and an oxygen-containing organic solvent where a bioactive agent is dissolved or dispersed in said mixture and where compounds form a liquid-crystal phase structure when contacting with a body fluid. Said compounds are applicable for preparing parenteral, non-parenteral and local slow-release drug reservoir compositions. The invention also covers a method of preparing and applying the compounds under the invention and to a method of the active agent delivery. ^ EFFECT: compounds under the invention provide prolonged controlled release of the active agent without "explosion" or "delay" effects in initial release. ^ 34 cl, 8 dwg, 20 tbl, 48 ex
OBJECTIVE: To develop gender and gestational age-specific reference standards for segmental limb lengths in term neonates.
METHODS: A cross-sectional study was conducted in a tertiary hospital in Tamil Nadu from June, 2019 to October, 2020. Term neonates were included through convenient sampling. Segmental length of upper and lower limbs was measured using non-stretchable steel measuring tape and total body length was measured with infantometer. Gestational age-specific mean length of all limb segments and segmental index with reference to total body length were calculated.
RESULTS: 950 term neonates were recruited. Their mean (SD) birth weight (kg) was 2.98 (0.34) and 17.5% were small for gestational age. Their mean (SD) total upper limb length (cm) and total lower limb length (cm) were 20.96 (1.22) and 19.6 (1.18), respectively. Gender-based difference was noted in total body and upper limb segment lengths. Segmental limb lengths had negligible positive correlation with gestational age but had a moderate positive correlation with total body length.
CONCLUSION: Gender and gestational age-specific segmental limb lengths standards may help to identify abnormal limb lengths in neonates at birth.
Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.